Active Ingredient History
5-trans-Prostaglandin E2 is the trans isomer of prostaglandin E2 and a common impurity in commercial lots of PGE1, that occurs naturally in some gorgonian corals. 5-trans-Prostaglandin E2 , a more potent than prostaglandin E2 in activating adenylate cyclase in NCB-20 cell homogenates. 5-trans PGE2 accelerates fibrinolysis by enhancing plasminogen activation mediated by tissue-type plasminogen activator and It also inhibits platelet aggregation/ 5-trans-Prostaglandin E2 is used as a substance for the isolation of new naturally occuring prostaglandin 5-trans-PGA2 and in the synthesis of 5-trans-PGF2a. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Labor, Obstetric (approved 1995)
Abortion, Incomplete (Phase 2)
Abortion, Induced (Phase 2)
Abortion, Missed (Phase 2)
Apgar Score (Phase 4)
Cervical Ripening (Phase 4)
Cervix Uteri (Phase 2)
Cesarean Section (Phase 4)
Contraception (Phase 4)
Delivery, Obstetric (Phase 4)
Drugs, Investigational (Phase 3)
Fetal Death (Phase 1/Phase 2)
Fetal Development (Phase 4)
Fetal Growth Retardation (Phase 3)
Fetal Membranes, Premature Rupture (Phase 3)
Hysterectomy (Phase 3)
Hysteroscopy (Phase 4)
Infant, Premature (Phase 4)
Intrauterine Devices (Phase 4)
Labor, Induced (Phase 4)
Labor, Obstetric (Phase 4)
Labor Pain (Phase 3)
Live Birth (Phase 4)
Myoma (Phase 3)
Neonatology (Phase 4)
Obstetric Labor Complications (Phase 4)
Ovulation Induction (Phase 4)
Pre-Eclampsia (Phase 1/Phase 2)
Pregnancy (Phase 4)
Uterine Myomectomy (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue